Literature DB >> 2030911

Loss of HPV-16 E7 dependence in cells transformed by HPV-16 E7 plus EJ-ras correlates with increased c-myc expression.

D Pim1, L Banks.   

Abstract

We have previously shown that continued expression of the HPV-16 E7 gene was required to maintain the transformed phenotype of primary baby rat kidney cells transformed by HPV-16 E7 plus EJ-ras. In this study we aimed to investigate the possible mechanisms by which cells could overcome this continued requirement for E7 expression. Using an inducible system for expression of the E7 gene we were able to generate cell lines no longer dependent on continued E7 expression. All such lines were still fully transformed, maintained inducible E7 expression and showed increased proliferative activity in the presence of HPV-16 E7 gene product. Further analysis has demonstrated a marked increase in the presence of c-myc protein in these cell lines when compared with the parental cells, suggesting a possible mechanism by which E7 dependence can be overcome.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2030911

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  3 in total

1.  Ras modifies proliferation and invasiveness of cells expressing human papillomavirus oncoproteins.

Authors:  Satoshi Yoshida; Naoko Kajitani; Ayano Satsuka; Hiroyasu Nakamura; Hiroyuki Sakai
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

2.  The p53-mediated G1 checkpoint is retained in tumorigenic rat embryo fibroblast clones transformed by the human papillomavirus type 16 E7 gene and EJ-ras.

Authors:  J W Peacock; S Chung; R G Bristow; R P Hill; S Benchimol
Journal:  Mol Cell Biol       Date:  1995-03       Impact factor: 4.272

3.  The lysine acetyltransferase GCN5 contributes to human papillomavirus oncoprotein E7-induced cell proliferation via up-regulating E2F1.

Authors:  Lijun Qiao; Qishu Zhang; Weifang Zhang; Jason J Chen
Journal:  J Cell Mol Med       Date:  2018-08-06       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.